Trade Codexis - CDXS CFD

Trading Conditions

• Spread: 0.05
• Long position overnight feeLong position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position-0.026179 %(-US$1.05)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position0.003957 %(US$0.16)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-US$1.05)

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  (US$0.16)

Key Stats

• Prev. Close: 2.64
• Open: 2.6
• 1-Year Change: -35.8%
• Day's Range: 2.6 - 2.7

Codexis Company profile

About Codexis, Inc.

Codexis, Inc. is a enzyme engineering company. The Company is engaged in discovering, developing and sells enzymes and other proteins. The Company operates through two segments: Performance Enzymes and Novel Biotherapeutics. The Company’s CodeEvolver technology platform accelerates biologic discovery through the transformation of a starting enzyme into a biocatalyst or therapeutic candidate. The Company has commercialized its CodeEvolver protein engineering technology platform and products in the pharmaceutical’s markets. The Company’s products include Codex HiFi Hot Start DNA Polymerase and Codex HiCap RNA Polymerase. The Company serves various industries, including food and food ingredients, animal feed, flavors, fragrances, and agricultural chemical.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Codexis, Inc. revenues increased 52% to $104.8M. Net loss decreased 11% to $21.3M. Revenues reflect Performance Enzymes segment increase of 88% to $90.5M, APAC segment increase from $25.4M to $61.1M, EMEA segment increase of 5% to $20.2M. Lower net loss reflects Performance Enzymes segment income increase from $3.8M to $33.1M.

Equity composition

Common Stock $0.0001 Par, 04/11, 100M auth., 35,573,003 issd. Insiders own approx. 16.85%. PO:TBA. 09/08, Company withdrawn its IPO.